CTEP is primarily used in research settings to study neurological disorders, particularly those related to glutamate signaling in the brain. It acts as a selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5), making it a valuable tool for investigating conditions such as autism, fragile X syndrome, anxiety, and Parkinson's disease. By blocking mGluR5, CTEP helps researchers understand the role of glutamate in synaptic plasticity and neuronal communication. Additionally, it has potential applications in preclinical studies for developing therapeutic strategies targeting mGluR5-related pathways. Its use is limited to experimental models, providing insights into the mechanisms underlying neuropsychiatric and neurodegenerative diseases.